Vanda Pharmaceuticals Inc.
- FDA Approves Hetlioz (tasimelteon) for the Treatment of Nighttime Sleep Disturbances in Smith-Magenis Syndrome - December 1, 2020
- FDA Approves Hetlioz: First Treatment for Non-24 Hour Sleep-Wake Disorder in Blind Individuals - January 31, 2014
- FDA Advisory Committee Recommends Approval of Hetlioz for the Treatment of Non-24-Hour-Disorder (Non-24) in the Totally Blind - November 15, 2013
- Vanda Announces Submission To FDA Of A New Drug Application For Tasimelteon For The Treatment Of Non-24-Hour Disorder In The Totally Blind - May 31, 2013
Drugs Associated with Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc. manufactures, markets and/or distributes more than 2 drugs in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.
Generic name: iloperidone
Drug class: atypical antipsychotics
|29 reviews||6.3 / 10|
Generic name: tasimelteon
Drug class: miscellaneous anxiolytics, sedatives and hypnotics
|1 review||10 / 10|
|For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective).|